DOCSLIB.ORG

YS% ,Xld M%Cd;Dka;S%L Iudcjd§ Ckrcfha .Eiü M;%H W;S Úfyi the Gazette of the Democratic Socialist Republic of Sri Lanka EXTRAORDINARY

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
YS% ,Xld M%Cd;Dka;S%L Iudcjd§ Ckrcfha .Eiü M;%H W;S Úfyi the Gazette of the Democratic Socialist Republic of Sri Lanka EXTRAORDINARY YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha .eiÜ m;%h w;s úfYI The Gazette of the Democratic Socialist Republic of Sri Lanka EXTRAORDINARY wxl 2144$20 - 2019 Tlaf;dan¾ ui 09 jeks nodod - 2019'10'09 No. 2144/20 - WEDNESDAY, OCTOBER 9, 2019 (Published by Authority) PART I : SECTION (I) — GENERAL Government Notifi cations Order No. 01 NATIONAL MEDICINES REGULATORY AUTHORITY ACT, NO. 5 OF 2015 Order under section 60 (2) BY VIRTUE of the powers vested in me by section 60 (2) of the National Medicines Regulatory Authority Act, No. 5 of 2015, I, Prof. Asita De Silva, Chairman of the National Medicines Regulatory Authority, do by this Order, inform the public that the medicines specifi ed in the Schedules here to have been registered with the National Medicines Regulatory Authority. Prof. ASITA DE SILVA Chairman, (For and on behalf of) National Medicines Regulatory Authority Colombo August 8, 2019 1A—PG 4679 - 257 (10/2019) This Gazette Extraordinary can be downloaded from www.documents.gov.lk 2 SCHEDULE - I P ART I:S COLUMN-I COLUMN-II COLUMN- COLUMN-IV COLUMN-V COLUMN- COL- COL- EC III VI UMN-VII UMN-VIII I . (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA -09.10.2019 REPUBLICOFSRILANKA SOCIALIST THE DEMOCRATIC OF . (I)-GAZETTEEXTRAORDINARY fldgi (^ Offi cial Name Brand Name Dosage Importer Manufacturer Man- Issue Reg. Form Name Country Date Type 1 BENZALKONIUM CHLORIDE,CETRIMID 0.01%,0.2% DRAPOLENE CREAM GlaxoSmithkiline Glaxo Smithkiline POLAND 24-Mar- Full I & fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜm;%h-2019'10'09 -YS%,xldm%cd;dka;s%liudcjd§ckrcfhaw;súfYI & fPoh Pharmaceuti clas Pharmaceuti clas 14 (Pvt) Ltd 2 CHLORHEXIDINE GLUCONATE 2.5%+ISOPROPYL SANISCUB C SOLUTION Ceyoka (Pvt) Ltd Sirmaxo INDIA 07-Jan-15 Full ALEOHOL BP 70% Chemicals Pvt Ltd 3 CHLOROXYLENOL LIQUID 4.8% APPLICATION DETTOL LIQUID N/A CDDEF Manu- SRI LANKA 01-Jan-18 Provisional facturers & Mer- chants for Rekitt Benkiser 4 DICHLOROBENZYL ALCOHOL 1.2mg STREPSILS LOZENGES Reckitt Reckitt Benckser THAILAND 28-Apr-15 Full (2,4)+AMYLMETACRESOL 0.6m+ LOZENGES HONEY & Benckiser Healthcare LEMON (Lanka) Ltd 5 DICHLOROBENZYL ALCOHOL 1.2mg STREPSILS COOL LOZENGES Reckitt Reckitt Benckiser THAILAND 28-Apr-15 Full (2,4)+AMYLMETACRESOL 0.6m+ LOZENGES Benckiser Healthcare UK (Lanka) Ltd Ltd 6 DICHLOROBENZYL ALCOHOL 1.2mg STREPSILS LOZENGES Reckitt Reckitt Benckser THAILAND 28-Apr-16 Full (2,4)+AMYLMETACRESOL 0.6m+ LOZENGES ORIGINAL Benckiser Healthcare (Lanka) Ltd 7 DICHLOROBENZYL ALCOHOL 1.2mg THERASIL LOZENGES George Steuart Plethico Pharma- INDIA 05-Apr-15 Full (2,4)+AMYLMETACRESOL 0.6m+ LOZENGES Health (Pvt) Ltd ceuti cals Ltd 8 GLIPE MIXTURE WITH OIL OF AMITHI B PBCO MORISON S SYRUP N/A M S J Industries SRI LANKA 14-Jun-17 Two Years 1% SODIUM BICARBONATE 1.0% & ZIMGIBAR GRIPE MIXTURE (Ceylon) (Pvt) Ltd OFFICINALE (GINGER) EXTRACT 0.48% FOR CHILDREN 4 9 INFANT CARMINATIVE SYRUP OIL OF ANETHI BPC MORISON S SYRUP N/A M S J Industries SRI LANKA 19-Oct-14 Full 0.1% SODIUM BICARBONATE BP 1% GRIPE MIXTURE (Ceylon) (Pvt) Ltd 10 INFANT CARMINATIVE SYRUP SODIUM GAMMA'S MIXTURE N/A Gamma Pharma- SRI LANKA 16-May- Full BICARBONATE +DIL OIL BP 0.1% GRIPE MIXTURE ceuti cals Pvt Ltd 14 SCHEDULE - I P ART 11 METHYL SALICYLATE 10.2% + MENTHOL 5.44% + FLANIL CREAM George Steuart Biolab Co Ltd THAILAND 24-May- Full I:S EUGENOL 1.36% Health (Pvt) Ltd 14 EC I . (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA -09.10.2019 REPUBLICOFSRILANKA SOCIALIST THE DEMOCRATIC OF . (I)-GAZETTEEXTRAORDINARY 12 METHYL SALICYLATE 6.3% ,MENTHOL 5.7% SALONPAS PATCH Akbar Hisamitsu Phar- JAPAN 06-Apr-15 Full fldgi (^ ,CAMPHAOR 1. 2% & TOCOPHEROL ACETATE Pharmaceuti cals maceuti cals Co (Pvt) Ltd Inc 13 I METHYL SALICYLATE 6.3% ,MENTHOL 5.7% SALONPAS PATCH Akbar Hisamitsu JAPAN 06-Apr-15 Full .eiÜm;%h-2019'10'09 -YS%,xldm%cd;dka;s%liudcjd§ckrcfhaw;súfYI & fPoh ,CAMPHAOR 1. 2% & TOCOPHEROL ACETATE Pharmaceuti cals Pharmaceuti cals (Pvt) Ltd Co Inc 14 METHYL SALICYLATE COMPOUND GEL WINTERPAN GEL N/A Akbar SRI LANKA 11-Apr-14 Full Pharmaceuti cals (Pvt) Ltd 15 ORAL REHYDRATION SALTS BP 21.5G MINERVA ORAL Emar Pharma Unicure INDIA 04-Jun-16 Full POWDER (Pvt) Ltd Ramadies (Pvt) Ltd 16 PARACETAMOL (PAEDIATIC) ORAL SOLUTION B.P PARACETOL LIQUID N/A Gamma SRI LANKA 22-Oct-14 Full 120MG/5ML Pharmaceuti cals Pvt Ltd 17 PARACETAMOL (PAEDRIATIC) ORAL SOLUTION B.P PANADOL SYRUP N/A Glaxo Wellcome SRI LANKA 16-Jun-18 Full 120MG/5ML SYRUP (Ceylon) Ltd 18 PARACETAMOL (PAEDRIATIC) ORAL SUSPENSION B.P ***** ORAL N/A M S J Industries SRI LANKA 08-Feb-18 Two Years 120MG/5ML-Elixir SOLUTION (Ceylon) (Pvt) Ltd 19 PARACETAMOL TABLETS 500MG PANADOL TABLETS N/A Smithkline SRI LANKA 17-Oct-16 Full Beecham (Pvt) Ltd 20 PARACETAMOL TABLETS BP 500MG ACETAMIN TABLETS Citi health Incepta 15-Aug-17 Two Years Imports (Pvt) Ltd Pharmaceuti cals Ltd 21 PARACETAMOL TABLETS BP 500MG MAXMOL TABLETS George Steuart Shefa Healthcare INDIA 18-Jan-14 Full Health (Pvt) Ltd (Pvt) ltd 22 PARACETAMOL TABLETS BP 500MG RAPISOL TABLETS N/A Astron (Pvt) Ltd SRI LANKA 13-Nov-15 Full 23 PEDIATRIC PARACETAMOL ORAL SOLUTION B.P MAXMOL ORAL George Steuart Shefa Healthcare INDIA 10-Jun-15 Full 120MG/5ML SUSPENSION Health (Pvt) Ltd (Pvt) ltd 3 4 SCHEDULE - II (GROUP A) (Contd.) P ART I:S COLUMN-I COLUMN-II COLUMN-III COLUMN-IV COLUMN-V COLUMN- COLUMN- COLUMN-VIII EC VI VII I . (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA -09.10.2019 REPUBLICOFSRILANKA SOCIALIST THE DEMOCRATIC OF . (I)-GAZETTEEXTRAORDINARY fldgi (^ Offi cial Name Brand Name Dosage Form Importer Name Manufacturer Man- Issue Date Reg. Type Country 1 ALBENDAZOLE TABLETS USP 400MG ALBEZIM TABLETS Tabrane Phar- Zim Laboratories INDIA 03-Oct-14 Full I maceuticals Ltd .eiÜm;%h-2019'10'09 -YS%,xldm%cd;dka;s%liudcjd§ckrcfhaw;súfYI & fPoh (Pvt) Ltd 2 ALUM.HYDR. DRIED GEL 300MG+MAG.ALUM. DIGENE MINT TABLETS Sunshine Abbott India Ltd INDIA 01-Jan-18 Provisional SILICATE HYDR 50MG+MAG.HYDR. 25MG FLAVOUR Healthcare lanka SIMETHICONE 25MG Ltd 3 ALUM.HYDR.306MG+MAG.HYDR VISCID ORAL Hemas Pharma- Indoco Remedies INDIA 18-Jan-17 Full 100MG+SIMETHICONE 25MG/5ML SUSPENSION ceuticals (Pvt) India Ltd 4 ALUM.HYDR.GEL 400MG+MAG.HYDR ANTAGTT DS ORAL Ceyoka (Pvt) Ltd Leben INDIA 28-May-14 Full 400MG+SIMETHICONE 50MG/5ML SUSPENSION Laboratories (Pvt) Ltd 5 ALUMINIUM +MAGNESIUM & SIMETHICONE GASTRIL- TABLETS Inter Pharm (Pvt) Inter Pharm (Pvt) SRI LANKA 27-Sep-17 Full TABLETS USP (LEMON Flavour) LEMON Ltd Ltd 6 ALUMINIUM +MAGNESIUM & SIMETHICONE GASTRIL-MINT TABLETS Inter Pharm (Pvt) SRI LANKA 27-Sep-15 Full TABLETS USP (Mint Flavour) Ltd 7 ALUMINIUM 400MG+MAGNESIUM 400MG) ANTAGIT TABLETS Ceyoka (Pvt) Ltd Leben INDIA 02-Mar-14 Full HYDROXIDE+SIMETHICONE 50MG Laboratories (Pvt) Ltd 8 ALUMINIUM HYD.GEL. CATOXYMAG-N ORAL Pharma Raptakos Brett & INDIA 05-Dec-14 Full BP 200MG+MAGNESIUM SUSPENSION Associates Company Ltd HYD.100MG+MAGNESIUM TRISLICATE BP 200MG+SODIUM ALGINATE BP 100MG 9 ALUMINIUM HYDROXIDE ZELLOX -11 ORAL Indoscan (Pvt) Hoe MALAYSIA 28-May-14 Full 8OOMG+MAGNESIUM HYDROXIDE SUSPENSION Ltd Pharmaceuticals 800MG+SIMETHICONE SDN BHD 10 ALUMINIUM HYDROXIDE ANTACIL GEL GEL Sonali & Sudesh Thai Nakorn THAILAND 19-Aug-15 Full 960MG+MAGNESIUM HYDROXIDE 330MG+ Patana Co Ltd SIMETHICONE 60MG 11 ALUMINIUM HYDROXIDE B.P 500MG ***** CHEWABLE State Phar- State SRI LANKA 22-Dec-14 Full TABLETS maceuticals Pharmaceuticals Manufacturer Manufacturer Corporation Corporation SCHEDULE - II (GROUP A) (Contd.) P ART 12 ALUMINIUM HYDROXIDE B.P 500MG **** TABLETS Kamazu (Pvt) B D H Industries INDIA 07-Nov-14 Full I:S Ltd Ltd EC I . (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA -09.10.2019 REPUBLICOFSRILANKA SOCIALIST THE DEMOCRATIC OF . (I)-GAZETTEEXTRAORDINARY 13 ALUMINIUM HYDROXIDE GEL BELCID ORAL George Steuart Biolab Co Ltd THAILAND 15-Oct-18 Full fldgi (^ 918MG+MAGNESIUM HYDROXIDE 300MG+ SUSPENSION Health (Pvt) Ltd SIMETHICONE 60MG 14 ALUMINIUM oxide 570MG+MAGNESIUM ADMAG ORAL Medinex (Pvt) T P Drugs THAILAND 07-Dec-14 Full I hydrox 300MG & SIMETHICONE 60MG ORAL SUSPENSION Ltd Laboratories .eiÜm;%h-2019'10'09 -YS%,xldm%cd;dka;s%liudcjd§ckrcfhaw;súfYI & fPoh SUSPENSION USP 15 ALUMINUM HYDROXIDE DRIED GEL GASTROGEL ORAL Sonali & Sudesh Aspen Pharma AUSTRA- 08-May-16 Full 500MG,MAGNESIUM TRISILICATE 240MG SUSPENSION (Pvt) Ltd LIA +MAGNESIUM HYDROXIDE 240MG IN10ML 16 AQUEOUS CREAM WITH GLYCERINE D-AQUA CREAM Panacea Panacea SRI LANKA 01-Jun-17 Two Years Medicals Medicals 17 AQUEOUS CREAM WITH GLYCERINE D-SOFT CREAM CREAM Panacea Panacea SRI LANKA 25-Apr-17 Two Years Medicals Medicals 18 AQUEOUS CREAM WITH GLYCERINE 2% AQUARIN CREAM Panacea Panacea SRI LANKA 27-Jun-17 Two Years Medicals Medicals 19 ASCORBIC ACID TABLETS BP 100MG C-TABS TABLETS Unical Ceylon Unical Ceylon SRI LANKA 18-Jul-16 Full (Pvt) Ltd (Pvt) Ltd 20 ASCORBIC ACID TABLETS BP 100MG ***** TABLETS Inter Pharm (Pvt) Inter Pharm (Pvt) SRI LANKA 11-May-17 Two Years Ltd Ltd 21 ASCORBIC ACID TABLETS BP 100MG ***** TABLETS M S J Industries M S J Industries SRI LANKA 01-Jan-17 Full (Ceylon) (Pvt) (Ceylon) (Pvt) Ltd Ltd 22 ASCORBIC ACID TABLETS BP 250MG CHEWCE TABLETS Darley Butler & Navana BANGLA- 30-Nov-16 Full Co Ltd Pharmaceuticals DESH Ltd 23 ASCORBIC AICD CHEWABLE TABLETS USP SHINE Vit. C 100 TABLETS Y S P Lanka Y S P Industries / MALAYSIA 30-Apr-17 Full 100MG (Pvt) Ltd SDN BHD l(Pvt) Ltd. 24 ASPIRIN GASTRO RESISTANT TABLETS BP CARVA TABLETS (EN.
Load more

Recommended publications
  • Cyproterone Art. 31
    Приложение I Списък на лекарствените продукти и форми 1 Държава членка Притежател на Наименование на INN/Активно Фармацевтична Начин на (ЕИП) разрешението за продукта вещество + форма приложение употреба Количество на активното вещество (в дозова единица) Австрия Bayer Austria Gmbh Androcur Depot Cyproterone Acetate Инжекционен Интрамускулно 300mg/3ml разтвор приложение Австрия Bayer Austria Gmbh Climen Cyproterone Acetate 1mg Обвита таблетка Перорално таблетка, Estradiol приложение Valerate 2mg таблетка| Estradiol Valerate 2mg таблетка Австрия Bayer Austria Gmbh Climen 28-Tage Cyproterone Acetate 1mg Обвита таблетка Перорално таблетка, Estradiol приложение Valerate 2mg таблетка| Estradiol Valerate 2mg таблетка Австрия Bayer Austria Gmbh Diane Mite Cyproterone Acetate 2mg Обвита таблетка Перорално таблетка, Ethinylestradiol приложение 35μg таблетка Австрия Bayer Austria Gmbh Minerva Cyproterone Acetate 2mg Обвита таблетка Перорално таблетка, Ethinylestradiol приложение 0,035mg таблетка Австрия Bayer Austria Gmbh Andro-Diane Cyproterone Acetate Таблетка Перорално 10mg таблетка приложение Австрия Bayer Austria Gmbh Androcur Cyproterone Acetate Таблетка Перорално 100mg таблетка приложение Австрия Bayer Austria Gmbh Androcur Cyproterone Acetate Таблетка Перорално 50mg таблетка приложение Австрия Gynial Gmbh Alisma Cyproterone Acetate 2mg Филмирана таблетка Перорално таблетка, Ethinylestradiol приложение 35μg таблетка 2 Държава членка Притежател на Наименование на INN/Активно Фармацевтична Начин на (ЕИП) разрешението за продукта вещество +
    [Show full text]
  • Aldosterone Enhances Renal Calcium Reabsorption by Two Types of Channels
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 66 (2004), pp. 242–250 Aldosterone enhances renal calcium reabsorption by two types of channels MARIE LECLERC,MICHELE` G. BRUNETTE, and DENIS COUCHOUREL Maisonneuve-Rosemont Hospital and University of Montreal, Canada Aldosterone enhances renal calcium reabsorption by two types transepithelial potential difference in the late segments of channels. of the nephron, reflecting a stimulation of the amiloride- Background. Aldosterone has been known for many years + + sensitive Na transport by the apical membranes. to increase sodium (Na ) reabsorption by the distal nephron. The present in vitro experiments investigated the effect of the In contrast to the abundant literature dealing with the + hormone on calcium (Ca2 ) transport by the luminal membrane antinatriuretic effect of aldosterone, data concerning its + of the rabbit nephron, independent of any systemic influence. action on Ca2 transport are relatively scarce. Clearance Methods. Proximal and distal tubules were incubated with studies showed either an increase in calciuria [2] or an + either aldosterone or the carrier. The luminal membranes of absence of significant change of Ca2 excretion [3, 4] af- these tubules were purified, vesiculated, and 45Ca uptake by these vesicles was subsequently measured. ter aldosterone administration. In a randomized study in Results. Treatment of the distal tubules with 10−8 mol/L al- male volunteers, Van Hamersvelt et al [5] compared the + + dosterone enhanced both 0.1 and 0.5 mmol/L Ca2 transport. effect of the Ca2 channel blocker felodipine, alone or The hormone action was abolished by tyrosine kinase inhibitors.
    [Show full text]
  • Pasar Farmasi Indonesia
    Company Update Audited FY December 2013 March 2014 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2013 audited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities of the Company.
    [Show full text]
  • Chemical-Specific Parameters Supporting Table May 2016 Analyte
    Regional Screening Level (RSL) Chemical-specific Parameters Supporting Table May 2016 Contaminant Molecular Weight Volatility Parameters Melting Point Density Diffusivity in Air and Water Partition Coefficients Water Solubility Tapwater Dermal Parameters H` (atm- Density Dia Diw Dia and Diw Kd Kd Koc log Kow S B τevent t* Kp 3 3 2 2 Analyte CAS No. MW MW Ref (unitless) m /mole) H` and HLC Ref VP VP Ref MP MP Ref (g/cm ) Density Ref (cm /s) (cm /s) Ref (L/kg) Ref (L/kg) Koc Ref (unitless) log Kow Ref (mg/L) S Ref (unitless) (hr/event) (hr) (cm/hr) K Ref Acephate 30560-19-1 1.8E+02 PHYSPRO 2.0E-11 5.0E-13 EPI 1.7E-06 PHYSPROP 8.8E+01 PHYSPROP 1.4E+00 CRC89 3.7E-02 8.0E-06 WATER9 1.0E+01 EPI -8.5E-01 PHYSPRO 8.2E+05 PHYSPROP 2.1E-04 1.1E+00 2.7E+00 4.0E-05 EPI Acetaldehyde 75-07-0 4.4E+01 PHYSPRO 2.7E-03 6.7E-05 PHYSPROP 9.0E+02 PHYSPROP -1.2E+02 PHYSPROP 7.8E-01 CRC89 1.3E-01 1.4E-05 WATER9 1.0E+00 EPI -3.4E-01 PHYSPRO 1.0E+06 PHYSPROP 1.3E-03 1.9E-01 4.5E-01 5.3E-04 EPI Acetochlor 34256-82-1 2.7E+02 PHYSPRO 9.1E-07 2.2E-08 PHYSPROP 2.8E-05 PHYSPROP 1.1E+01 PubChem 1.1E+00 PubChem 2.2E-02 5.6E-06 WATER9 3.0E+02 EPI 3.0E+00 PHYSPRO 2.2E+02 PHYSPROP 3.1E-02 3.4E+00 8.2E+00 5.0E-03 EPI Acetone 67-64-1 5.8E+01 PHYSPRO 1.4E-03 3.5E-05 PHYSPROP 2.3E+02 PHYSPROP -9.5E+01 PHYSPROP 7.8E-01 CRC89 1.1E-01 1.2E-05 WATER9 2.4E+00 EPI -2.4E-01 PHYSPRO 1.0E+06 PHYSPROP 1.5E-03 2.2E-01 5.3E-01 5.1E-04 EPI Acetone Cyanohydrin 75-86-5 8.5E+01 PHYSPRO 8.1E-08 2.0E-09 PHYSPROP 3.4E-01 PHYSPROP -1.9E+01 PHYSPROP 9.3E-01 CRC89 8.6E-02 1.0E-05 WATER9 1.0E+00
    [Show full text]
  • Pasar Farmasi Indonesia
    Not all collagen is the same, it’s time to choose the right one Company Update Unaudited YTD September 2014 October 2014 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 September 2014 unaudited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.
    [Show full text]
  • Environmental Health Criteria 206 Methyl Tertiary-Butyl Ether -J
    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY Environmental Health Criteria 206 Methyl tertiary-Butyl Ether -J. l \r LNTER-ORGAN1ZATON PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS I JiVJ A cooperative agreement among UNEP, ILO, FAO, WHO, UNIDO, UNITAR and OECD THE ENVIRONMENTAL HEALTH CRITERIA SERIES Acetaldehyde (No. 167, 1995) Chiorofluorocarbons, partially halogenated Acetonitrile (No. 154, 1993) (ethane derivatives) (No. 139, 1992) Acrolein (No. 127, 1991) (methane derivatives) (No. 126, 1991) Acrylamide (No. 49, 1985) Chloroform (No. 163, 1994) Acrylic acid (No. 191, 1997) Chlorophenols (No. 93, 1989) Acrylonitrile (No. 28, 1983) Chlorothalonil (No. 183, 1996) Aged population, principles for evaluating Chromium (No. 61, 1988) the effects of chemicals (No. 144, 1992) Chrysotile asbestos (No. 203, 1998) Aldicarb (No. 121, 1991) Copper (No. 200, 1998) Aldrin and dieldrin (No. 91, 1989) Cresols (No. 168, 1995) Allethrins (No. 87, 1989) Cyhalothrin (No. 99, 1990) Aluminium (No. 194, 1997) Cypermethrin (No. 82, 1989) Amitrole (No. 158, 1994) Cypermethrin, alpha- (No. 142, 1992) Ammonia (No. 54, 1986) DOT and its derivatives (No. 9, 1979) Anticoagulant rodenticides (No. 175, 1995) DOT and its derivatives - Arsenic (No. 18, 1981) environmental aspects (No, 83, 1989) Asbestos and other natural mineral fibres Deltamethrjn (No. 97, 1990) (No. 53, 1986) Demeton-S-methyl (No. 197, 1997) Barium (No. 107, 1990) Diaminotoluenes (No. 74, 1987) Benomyl (No. 148, 1993) Diazinon (No. 198, 1997) Benzene (No. 150, 1993) 1,2-Dibromoethane (No. 177, 1996) Beryllium (No. 106, 1990) Oi-n-butyl phthalate (No. 189, 1997) Biomarkers and risk assessment: concepts 1 ,2-Dichloroethane and principles (No. 155, 1993) (No. 62, 1987, 1St edition) Blotoxins, aquatic (marine and freshwater) (No.
    [Show full text]
  • TOXICOLOGICAL PROFILE for METHYL Tert-BUTYL ETHER
    TOXICOLOGICAL PROFILE FOR METHYL tert-BUTYL ETHER U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry August 1996 METHYL tert-BUTYL ETHER ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. METHYL tert-BUTYL ETHER iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 vi *Legislative Background The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on April 29, 1996 (61 FR 18744). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 199l (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486).
    [Show full text]
  • PT Kalbe Farma Tbk. Dan Entitas Anaknya/And Its Subsidiaries
    PT Kalbe Farma Tbk. dan Entitas Anaknya/ and its Subsidiaries Laporan keuangan konsolidasian tanggal 30 Juni 2019 dan untuk periode yang berakhir pada tanggal tersebut (Belum Diaudit)/ Consolidated financial statements as of June 30, 2019 and for the period then ended (Unaudited) The original consolidated financial statements included herein are in the Indonesian language. PT KALBE FARMA Tbk. DAN ENTITAS ANAK NYA PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES LAPORAN KEUANGAN KONSOLIDASIAN CONSOLIDATED FINANCIAL STATEMENTS TANGGAL 30 JUNI 2019 DAN AS OF JUNE 30, 2019 AND UNTUK PERIODE YANG BERAKHIR PADA FOR THE PERIOD THEN ENDED (UNAUDITED) TANGGAL TERSEBUT (BELUM DIAUDIT) Daftar Isi Table of Contents Halaman/ Page Laporan Posisi Keuangan Konsolidasian ......................... 1-3 ............ Consolidated Statement of Financial Position Laporan Laba Rugi dan Penghasilan Consolidated Statement of Profit or Loss Komprehensif Lain Konsolidasian ............................. 4-5 ..................... and Other Comprehensive Income Laporan Perubahan Ekuitas Konsolidasian ..................... 6 ........... Consolidated Statement of Changes in Equity Laporan Arus Kas Konsolidasian ..................................... 7-8 ..................... Consolidated Statement of Cash Flows Catatan Atas Laporan Keuangan Konsolidasian .............. 9-139 ....... Notes to the Consolidated Financial Statements *************************** g PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES LAPORAN POSISI KEUANGAN KONSOLIDASIAN CONSOLIDATED
    [Show full text]
  • Kalbe Farma (KLBF
    Company Update Indonesia 11 November 2019 Healthcare | Pharmaceuticals Kalbe Farma (KLBF IJ) Buy (Maintained) Ground Checks: Investment In The Future; BUY Target Price (Return) IDR2,000 (+25%) Price: IDR1,595 Market Cap: USD5,309bn Avg Daily Turnover (IDR/USD) 49bn/3.5m Maintain BUY and IDR2,000 TP, 25% upside plus c.2% yield. We recently Analysts visited the Kalbio Global Medika (KGM) production facility in Cikarang, West Java. KGM, KLBF’s subsidiary, specialises in biosimilar products, in Jessica Pratiwi partnership with South Korean biotechnology R&D company, Genexine Inc. +6221 5093 9845 The facility has a land area of 11,000 sqm and 195 employees. The site visit [email protected] was hosted by Daniel Iskandar Wirawan (site head) and Fahrizal Nugraha (QC manager) from KGM, and Megawati Purnama and Marcella Cloudia (KLBF investor relations team). Michael W Setjoadi Higher biosimilar sales to support declining pharma margins. Competition +6221 5093 9844 in the biosimilar market is not as strong as in generic drugs given the high [email protected] development costs and production complexity (c.2 months/batch). The two local competitors are Combiphar Dong-A and Daewoong Infion. EBIT margin Share Performance (%) in this segment is also much more attractive at 23-25% vs 8-10% for unbranded YTD 1m 3m 6m 12m generics. Absolute 4.3 (2.8) 10.8 5.7 14.0 Currently, 90% of KLBF’s biosimilars, mainly the Hemapo drug (c.3,000 Relative 4.7 (5.5) 11.5 7.8 10.2 units/year), are for National Social Health Insurance (JKN) patients.
    [Show full text]
  • Company Performance Company Performance
    Company Performance YTD September 2008 Contents Part 1 Kalbe at a Glance Part 2 Pharmaceutical Industry Overview Part 3 Business Overview A. Prescription Pharmaceuticals B. Nutritionals C. Consumer Health D. Distribution and Packaging Part 4 Operational Overview Part 5 Growth Drivers Part 6 Financial Overview Part 7 Recent Activities PtPart 8 FtFuture OtlkOutlook 2 Part 1 Kalbe at a Glance 3 Comppyggany Highlights Largest Publicly-Listed ♦ More than 42-year old pharmaceutical company with long track record of profitable growth. Pharmaceutical ♦ After the merger with PT Dankos Laboratories Tbk. and PT Enseval effective on December 16, Company in Southeast 2005, Kalbe has become the largest publicly-listed pharmaceutical company in Southeast Asia with approximately US$ 1 billion market capitalization in the past year. Asia 3 ♦ Lttltif2Large target population of 235 million in In dones ia, an d 570 million in Sou theas t As ia. Substantial Market ♦ OTC and prescription pharma in the Indonesian and Southeast Asian markets expected to grow Opportunity annually at 10% and 13% respectively over the next several years. ♦ The market leader in Indonesian prescription pharma market with 13% market share as well as a Market Leading leader in consumer health market with 16% OTC market share, 9% share in nutrition market and Positions in Indonesia 30% in energy drink market for the first semester in year 2008. ♦ Unrivaled health distribution network which directlyyy and indirectly covers more than 1 million outlets. Strong, Diversified, ♦ Consumer health portfolio which includes 13 market leading OTC brands in 7 main therapeutic categories, the market leading brand in pregnant nutrition and clinical foods, and the leading energy High Growth Product drink in Indonesia.
    [Show full text]
  • The Effect of Dosing Regimen on Outcomes of Vitamin D Supplementation Trials a Study of Current Literature
    Faculty of Medicine The effect of dosing regimen on outcomes of vitamin D supplementation trials A study of current literature — Anette Uhlving Larsen Master thesis in Medicine (MED-3950) June 2019 Supervisor: Professor Rolf Jorde, Institute of Clinical Medicine Abstract Results from observational studies have indicated associations between vitamin D and extra- skeletal outcomes, including respiratory tract infections (RTI) and all-cause mortality. However, available trial-data have shown inconsistent results. The main objective of this thesis was to investigate whether a beneficial effect of daily supplementation of vitamin D on RTI and all-cause mortality could have been masked by the use of less frequent supplementation intervals. This thesis included data from double-blinded, randomized controlled trials (RCTs) published in the last 10 years. Eligible trials were identified through screening of the reference lists of systematic reviews of meta-analyses (MAs), and of reference lists of MAs on the selected outcomes included in these reviews. Also, additional searches were performed to ensure that also recently published RCTs, not identified in a previous step of the search strategy, were considered for inclusion. The search strategy was designed to promote selection of trials of adequate methodological quality. To be included the record had to be written in English and report results of a double-blinded placebo-controlled RCT with vitamin D supplementation in a human population. Studies including pregnant women or assessing the effect of prenatal supplementation were not included, nor were studies including populations with chronic kidney disease and/or other diseases known to affect the conversion of active metabolites of vitamin D.
    [Show full text]
  • PT Kalbe Farma Tbk
    20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT of the FPP manufacturer Part 1 General information Manufacturers details Company information Name of PT. Kalbe Farma Tbk. manufacturer and Delta Silicon Industrial Park address Jl. M. H. Thamrin Blok A3-1, Lippo Cikarang, Bekasi 17550, Indonesia. PO. BOX 371, Bekasi 17037, Indonesia Phone 62-21-89907333 (24 hours) Fax 62-21-8972874 GPS Coordinate ; 6°19’15.4175” South, 107°7’0.1182” East Corporate KALBE Building address of Jl. Let.Jend. Suprapto Kav.4, Central Jakarta 10510 manufacturer PO BOX 3105 JAK, Jakarta , Indonesia Phone 62-21-42873888 – 89 Fax 62-21-42873680 Inspected site Address of As above inspected manufacturing site Unit / block / Production line 8A workshop number WHOPIR PT.Kalbe Farma Tbk, Indonesia 24, 25 and 28 May 2018 This inspection report is the property of the WHO Contact: [email protected] Page 1 of 16 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Manufacturing • CPOB Cairan oral non beta laktam (GMP non beta lactam oral liquid) license number Certificate Number: 4655/CPOB/A/XII/15 License Number: HK.07.IF/V/109/11 License Date: 18 May 2011 Valid until: 31 Dec 2020 • CPOB Kapsul keras non beta laktam (GMP non beta lactam hard capsule) Certificate Number: 4654/CPOB/A/XII/15 License Number: HK.07.IF/V/109/11 License Date: 18 May 2011 Valid
    [Show full text]